MT Group Signs Contract with Ørsted to Build Large-scale CO2 Capture and Storage Facility in Denmark
MT Group, an EPC contractor engaged in strategic energy and industrial infrastructure projects across Europe, has signed a contract with Danish energy leader Ørsted for the engineering and construction of Balance of Plant (BoP) piping and equipment for a carbon capture facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915027054/en/
Mindaugas Zakaras, CEO of MT Group (Photo: Business Wire)
"The signing of this contract is a significant milestone for MT Group and a strong testament to our commitment to driving the renewable energy transition across Europe," says Mindaugas Zakaras, CEO of MT Group.
Advancing Global Efforts to Combat Climate Change
This contract is part of Ørsted's 20-year agreement with the Danish Energy Agency (DEA) for the ambitious carbon capture and storage (CCS) project, the ‘Ørsted Kalundborg CO2 Hub.’ It aims to capture and store 430,000 tons of CO2 annually from two Ørsted Power stations. The captured CO2 will be transported to Northern Lights in Norway for geological storage, contributing to global efforts to combat climate change.
Under this agreement, MT Group will handle the engineering and construction of piping for the BoP equipment for the CO2 capture and storage facility including installation of BoP equipment. Responsibilities include finalizing the BoP facility's design and integrating it with the existing woodchip-fired boiler plant and the new CO2 capture and storage facility at Asnæsværket, Denmark.
MT Group will also oversee the procurement, supply, construction, and installation of the entire cooling and steam systems, including pipelines, to the interface of the CO2 capture and storage units. Additionally, the company will ensure the scope of supply undergoes rigorous testing and commissioning to meet all regulatory and operational standards before it becomes fully operational.
Strengthening MT Group's Renewable Energy Portfolio
This contract aligns with MT Group’s strategic focus on the renewable energy transition. “We have firmly established MT Group as a strong and reliable EPC contractor, particularly in the development of complex natural gas and LNG projects across Europe. This contract marks a significant step in our expansion in the green energy markets and strengthens our position in this rapidly growing area,” adds Mindaugas Zakaras.
MT Group is a leading EPC contractor in critical energy and industrial infrastructure projects across Europe. The company is also a founding partner in one of the largest Renewable Energy undertakings in the world. Green Energy Park will produce some of the most cost competitive Green Hydrogen at the gigawatts scale, servicing the decarbonization needs of the hard to abate sectors, including transport and power across Europe and elsewhere around the world.
MT Group’s expertise extends to the development and construction of renewable energy, hydrogen and carbon capture facilities, positioning the company at the forefront of sustainable engineering solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915027054/en/
Contacts
Migle Poskute Klimasauskiene
Migle Poskute Klimasauskiene
M.: +370 656 57230
E.: m.klimasauskiene@mtgroup.lt
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom